What You Should Know:
- Medtronic, a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval of its Percept™ RC Deep Brain Stimulation (DBS) system.
- The rechargeable neurostimulator is the latest innovation in the Medtronic Percept™ family, which includes the Percept™ PC neurostimulator, BrainSense™ technology, and SenSight™ directional leads. The Percept™ family is the only sensing-enabled DBS system on the market, allowing the physician to personalize treatment for patients with movement disorders such as Parkinson’s disease, essential tremor, and dystonia as well as epilepsy.
Medtronic’s Perception RC with BrainSense Spearheads Cutting-Edge Management for Pathological Tremor
DBS utilizes a surgically implanted medical device, resembling a cardiac pacemaker. Medtronic’s Percept™ neurostimulators employ slender wires to transmit electrical signals to specific brain targets affected by neurological disorders such as Parkinson’s disease. The Percept™ RC, the smallest and thinnest dual-channel neurostimulator for DBS, incorporates BrainSense™ technology to capture and record brain signals.
This allows healthcare providers to tailor and personalize therapy based on evolving patient needs. The Percept™ RC battery, featuring Medtronic’s patented technology, offers a service life of at least 15 years with consistent and fast recharge performance, exhibiting less battery fade than other rechargeable devices. Patients can achieve rapid recharging from 10% to 90% full charge in less than an hour. Notably, Medtronic was the first in the U.S. to provide full-body MR Conditional DBS systems, enabling patients to undergo safe scans anywhere on the body under specific conditions. This is crucial as nearly 70 percent of all DBS-eligible patients may require an MRI as part of their essential care.
“Our DBS therapy with exclusive BrainSense™ technology can help control debilitating tremors for people living with Parkinson’s, providing patients with the ability to physically engage in everyday moments – something many of us unintentionally take for granted,” said Amaza Reitmeier, vice president and general manager, Brain Modulation within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. “We are transforming brain modulation through sensing-enabled DBS and will continue to drive therapy innovation with the goal of many more peoples’ lives improved with Medtronic DBS therapy.”
